BetterLife Enrolls First Patient in Interferon Alpha-2b COVID-19 Trial in Chile

BetterLife Pharma Inc. announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc., and Pontificia Universidad Católica de Chile have enrolled the first patient in the Phase I portion of the Phase I-II randomized placebo controlled in COVID-19 patients. The trial tests BetterLife’s proprietary inhaled interferon alpha-2b product, AP-003.